Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season
NeOnc Technologies has scheduled a November 17, 2026 End-of-Phase 1 FDA meeting for NEO212 to discuss the proposed Phase 2 population, study design, endpoints, and dose selection. The company completed dose escalation and selected 610 mg as the recommended Phase 2 dose after a dose-limiting toxicity occurred at 810 mg. Separately, the piece recaps a compassionate-use case in Abu Dhabi where physicians reported early improvement in a three-year-old brain tumor patient treated with NEO100, and prior executive open-market purchases of roughly $629,000 in stock following positive Phase 2a results.
Key figures
- Drug Name
- NEO212
- Phase Of Trial
- End-of-Phase 1
- Dlt dose
- 810 mg
- Fda meeting date
- November 17, 2026
- Recommended phase2 dose
- 610 mg
- Insider open market purchases
- $629,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.